Navigation Links
ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells
Date:9/1/2010

ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS... -- YOKOHAMA, Japan, September 1, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells

 

YOKOHAMA, Japan, September 1, 2010 /PRNewswire/ -- ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) is pleased to announce a new line of products to be launched in the autumn of 2010, offering neuronal cells derived from human iPS (induced pluripotent stem) cells.

Since April 2009, ReproCELL has been manufacturing iPS cell-derived cardiomyocytes for drug toxicity testing as the world's first drug discovery support business provider founded on iPS cells. The prospective new offering of neuronal cells is the second line of services to be introduced by the company, and is a considerable expansion of their scope of business. ReproCELL will be the first in the world to offer iPS cell derived neuronal cells, and, more specifically, will provide dopaminergic neurons, motor neurons, and cerebral nerves.

ReproCELL's Representative Director and CEO Chikafumi Yokoyama PhD commented, "Despite the constant rise of patients with neurodegenerative disorders such as Alzheimer's and Parkinson's Disease, fundamental therapies are still sought after in this ageing society. Through offering human iPS cell derived neuronal cells to the pharmaceutical industry, we hope to enable more effective screening of various neuroactive therapeutic compounds, thereby contributing to the development of new medicines."

In addition, the company welcomes its new scientific advisor, Professor Sian Harding at the National Heart and Lung Institute, Imperial College London, a leading expert in pluripotent stem-cell derived cardiomyocytes. Through this new collaboration, the company aims to accelerate further research and development in the use of iPS cells in this field.

Website: http://www.reprocell.net/


'/>"/>
SOURCE ReproCELL Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 Australian-US drug discovery and ... today the appointment of a new Chairman, Mr John ... , effective immediately. James Garner , has ... Director and former Acting CEO, Mr Iain Ross , ... Director. --> James Garner , has also been ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Club, takes place February 5-6 at the University’s student center, Kehr Union, ... such as workshops and competitions for ample networking, learning and collaborating opportunities. ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016 ContraVir ... focused on the development and commercialization of targeted antiviral ... CEO & Investor Conference 2016, to be held February ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... on February 10-11, 2016. James Sapirstein , ...
(Date:2/4/2016)... Brooklyn, NY (PRWEB) , ... February 04, 2016 , ... ... cuvettes for over 10 years. What sets them apart from other cuvette ... that is posted on their website. On top of this steady flow of ...
Breaking Biology Technology:
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/13/2016)... 2016 http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ... the  "India Biometrics Authentication & Identification ...  report to their offering.  ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ...
(Date:1/7/2016)... -- This BCC Research report studies the global as ... identifying newer markets and exploring the expansion of the ... Includes forecast from 2015 to 2020. Use ... the expansion of the present application market for various ... technology, determine its current market size, and estimate the ...
Breaking Biology News(10 mins):